Islatravir

Generic Name: Islatravir

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₁₂FN_₅O_₃

CAS Number: 865363-93-5

Unique Ingredient Identifier: QPQ082R25D

Background: Islatravir is under investigation in clinical trial NCT04233216 (Doravirine/islatravir (DOR/ISL) in Heavily Treatment-experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

Phase 2

Completed

Conditions: HIV-1 Infection

Interventions: Drug: Placebo to Islatravir
Drug: Islatravir
Drug: Doravirine
Drug: Placebo to Doravirine
Drug: Lamivudine
Drug: Placebo to Lamivudine
Drug: Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate
Drug: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate
Drug: Doravirine/Islatravir

First Posted Date: 2017-09-05

Last Posted Date: 2023-03-29

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 123

Registration Number: NCT03272347

Locations: 🇺🇸
North Texas Infectious Diseases Consultants, PA ( Site 0103), Dallas, Texas, United States
🇺🇸
Whitman Walker Clinic ( Site 0108), Washington, District of Columbia, United States
🇺🇸
Orlando Immunology Center (OIC) ( Site 0105), Orlando, Florida, United States

and more 23 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy